PT-141 vs Oxytocin

PT-141

Melanocortin-receptor agonist that works on desire in the brain, not blood flow in the pelvis. FDA-approved as Vyleesi for premenopausal HSDD.

Best for

Best when desire and arousal are the goal; PT-141 acts on the brain’s melanocortin arousal pathway and is FDA-approved (Vyleesi).

Oxytocin

The body's bonding hormone, repurposed as intranasal spray for social and intimacy effects. The hype outpaces the trial data.

Best for

Best for connection, bonding, and situational closeness rather than a reliable libido effect.

PT-141

FDA-approved in 2019 for HSDD in premenopausal women based on the RECONNECT trials (Palatin Technologies, two Phase 3 studies with about 1,200 women combined). The female indication is the licensed one; male use is entirely off-label but the central mechanism transfers. Long-term data beyond a year is thin.

Oxytocin

Many small trials, several large null replications. The original autism-spectrum and 'trust hormone' studies have failed to replicate at the magnitude they originally claimed. Intranasal oxytocin for HSDD and partner bonding has small RCT support but nothing close to regulatory-grade. The IV form is approved for obstetric use; the spray is research-grade only.